Scaling from R&D into your first clinical trial

Scaling from R&D into your first clinical trial?

November 11, 2026•12 min read

Scaling from R&D into Your First Clinical Trial?

Moving from research and development into a first clinical trial is a significant milestone for any biotechnology or therapeutic goods company. It marks the transition from exploratory scientific work towards the controlled development of an investigational product intended for use in humans. Alongside the scientific and technical challenges, this transition introduces new regulatory responsibilities, quality requirements, documentation expectations and operational demands.

The systems that support early research are not necessarily sufficient for clinical development. Research teams may have relied on informal processes, shared folders, working documents and established laboratory practices. These arrangements can become inadequate when activities need to be controlled, reviewed, documented and demonstrated to meet applicable Good Clinical Practice (GCP), Good Manufacturing Practice (GMP) and other regulatory requirements.

However, moving into clinical development does not mean that every organisation needs to implement a fully mature pharmaceutical quality system immediately. The challenge is to establish the right foundations, introduce appropriate controls and develop the infrastructure needed for the next stage without creating unnecessary complexity.

A planned, phase-appropriate approach helps organisations make this transition efficiently while protecting data integrity, product quality, participant safety and regulatory compliance.

Understanding the Transition from R&D to Clinical Development

Research and development environments are designed to generate knowledge, investigate scientific hypotheses and establish whether a product or technology has potential. Processes may change frequently as experiments are refined, analytical methods are developed and new information becomes available.

Clinical development introduces a different level of control. Activities involving an investigational product, clinical trial documentation, manufacturing, testing and participant-related information must be conducted under appropriate procedures and regulatory oversight.

The organisation must be able to demonstrate what was done, who performed the activity, which materials and methods were used, what results were obtained and how decisions were made. Records must be sufficiently complete and reliable to support review, investigation and regulatory assessment.

The transition therefore requires more than preparing a clinical trial application or engaging a clinical research organisation. It involves examining the organisation's existing capabilities and identifying the systems, responsibilities and controls needed to support the proposed trial.

The precise requirements will depend on the product, development stage, trial design, manufacturing arrangements and jurisdiction. A biotechnology company developing a biological product, for example, may have different technical and quality considerations from a company investigating a small-molecule medicine or medical device.

Understanding these differences early helps prevent gaps from emerging as the programme advances.

Establishing a Phase-Appropriate Pharmaceutical Quality System

A Pharmaceutical Quality System (PQS) provides the framework for managing quality-related activities throughout the product lifecycle. As a company approaches its first clinical trial, it should assess whether its existing quality arrangements are suitable for the activities it intends to perform.

A phase-appropriate PQS does not mean having fewer controls than required. It means designing a system that reflects the organisation's current activities, risks and regulatory obligations, while allowing it to develop as the programme progresses.

Fundamental elements commonly include:

  • Defined quality responsibilities and management oversight.

  • Controlled procedures, policies and work instructions.

  • Document and record management.

  • Personnel training and competency records.

  • Deviation and nonconformance management.

  • Corrective and preventive action.

  • Change control.

  • Risk management.

  • Supplier and service provider oversight.

  • Equipment and facility controls, where applicable.

  • Validation and qualification appropriate to the activities.

  • Internal review and continual improvement.

The system should establish clear expectations for personnel and provide evidence that regulated activities are performed consistently.

For organisations with limited quality infrastructure, the first step is often a structured gap assessment. This compares current practices with the requirements relevant to the planned clinical development activities. The findings can then be prioritised according to regulatory importance, product quality risk and implementation timing.

This avoids the common problem of creating a large collection of procedures before the organisation has established which controls are actually needed.

Building a Compliant Document Management Structure

Documentation becomes increasingly important as an organisation moves towards clinical development. Information generated during research may eventually contribute to product characterisation, manufacturing development, analytical testing, regulatory submissions and clinical trial planning.

If records are incomplete, difficult to retrieve or inadequately controlled, the organisation may struggle to demonstrate the reliability and traceability of its development activities.

A document management system should provide a defined method for creating, reviewing, approving, issuing, revising and retiring controlled documents. It should also establish how records are stored, protected, retrieved and retained.

Documents may include standard operating procedures, policies, specifications, protocols, reports, forms, work instructions and technical records. The organisation should distinguish controlled documents from informal working materials and establish clear rules for each.

A compliant document management structure should address several practical considerations:

Document ownership: Each controlled document should have an identified owner responsible for its content and ongoing suitability.

Review and approval: Documents should be reviewed and approved by personnel with appropriate knowledge and authority before becoming effective.

Version control: Personnel must be able to identify the current approved version and avoid using obsolete instructions.

Access and permissions: Access should be appropriate to individual responsibilities, particularly where electronic systems are used.

Training: Relevant personnel should receive appropriate training before performing activities governed by new or revised procedures.

Record retention: Records should be retained in accordance with applicable regulatory requirements and organisational procedures.

An electronic document management system may be appropriate, depending on the organisation's size, complexity and anticipated growth. However, selecting software is only one part of the process. The organisation must also define its procedures, responsibilities, access controls and system governance.

Where electronic systems are used for regulated activities, their intended use and applicable validation or assurance requirements must be considered. A digital platform does not become compliant simply because it stores documents electronically.

Understanding GMP Requirements Before Clinical Manufacturing

One of the most important considerations before a first clinical trial is determining how the investigational product will be manufactured, tested, packaged and supplied.

If the organisation intends to manufacture the product itself, it must establish the facilities, equipment, personnel, procedures and quality oversight required for the relevant manufacturing activities. If manufacturing is outsourced, the organisation still needs appropriate oversight of the contract manufacturer and a clear understanding of responsibilities.

GMP requirements depend on the product, manufacturing process, development stage and applicable regulatory framework. Clinical trial material must be manufactured and controlled under the requirements that apply to its intended use and jurisdiction.

Important considerations may include:

  • Raw material and component control.

  • Manufacturing process documentation.

  • Batch records and traceability.

  • Equipment suitability and maintenance.

  • Environmental and facility controls, where relevant.

  • Analytical methods and specifications.

  • Process and cleaning validation, where applicable.

  • Deviation investigation and change control.

  • Batch review and disposition.

  • Storage, transport and distribution conditions.

For early clinical development, the level of process knowledge may still be evolving. Nevertheless, the organisation needs a scientifically justified approach to identifying critical quality attributes, understanding process risks and establishing appropriate controls.

The transition from laboratory-scale development to clinical manufacturing should be planned carefully. Differences in equipment, scale, materials and operating conditions can affect product characteristics and process performance. These factors should be evaluated and documented as the manufacturing process develops.

Preparing for GCP and Clinical Trial Responsibilities

Clinical trials introduce requirements that extend beyond manufacturing and product quality. Good Clinical Practice provides an important framework for protecting trial participants and ensuring the credibility and reliability of clinical trial data.

The sponsor has significant responsibilities for the overall conduct and oversight of a clinical trial. These responsibilities may include selecting and overseeing service providers, ensuring appropriate trial documentation, maintaining oversight of trial conduct and addressing issues that could affect participant safety or data reliability.

Organisations preparing for their first trial should understand the responsibilities associated with sponsorship, even when clinical activities are delegated to external providers.

A clinical research organisation may support trial management, monitoring or other activities, but outsourcing does not remove the sponsor's overall accountability for appropriate oversight.

Key preparation activities can include establishing responsibilities, assessing service providers, reviewing trial documentation, managing essential records and ensuring that personnel understand the procedures relevant to their roles.

The organisation should also consider how safety information, protocol deviations, significant issues and changes will be communicated, assessed and managed.

Clinical trial readiness requires coordination between scientific, clinical, regulatory, quality and operational functions. These activities should not be developed in isolation.

Managing Data Integrity Across Development Activities

Data generated during R&D may become important evidence supporting clinical development decisions and regulatory submissions. Maintaining reliable records from the beginning reduces uncertainty when information needs to be reviewed or reconstructed.

Data integrity principles apply to paper-based and electronic information. Records should be attributable, legible, contemporaneous, original or appropriately verified, and accurate.

In practice, this means ensuring that personnel can be identified as the individuals who performed or recorded an activity, that information is recorded at the time the work occurs, and that original observations are preserved.

Changes to records should be traceable and should not obscure the original information. Electronic systems should have appropriate access controls, audit trails and record protection according to their intended use and applicable requirements.

Organisations should assess where critical development data are generated and stored. This may include laboratory notebooks, analytical instruments, spreadsheets, electronic laboratory systems, external testing laboratories and contract research organisations.

A data integrity assessment can help identify risks associated with uncontrolled spreadsheets, shared user accounts, incomplete audit trails, undocumented calculations and inconsistent recordkeeping practices.

Addressing these issues before clinical development becomes more complex is generally more manageable than attempting to reconstruct historical records later.

Assessing Suppliers and External Service Providers

Early-stage organisations frequently rely on external providers for specialist activities. These may include contract manufacturers, analytical laboratories, clinical research organisations, consultants, technology providers and specialist testing services.

The organisation should identify which external activities could affect product quality, participant safety, data integrity or regulatory compliance. Providers should be assessed according to the nature and risk of the service they perform.

Supplier qualification may involve reviewing relevant experience, quality systems, technical capability, regulatory history and the suitability of facilities or equipment. The depth of assessment should reflect the criticality of the outsourced activity.

Where responsibilities are shared, they should be clearly documented. Quality or technical agreements may be appropriate to define activities, communication pathways, record access, deviation reporting, change notification and oversight responsibilities.

A provider's reputation or previous experience does not remove the need for appropriate assessment. Organisations must understand what work is being performed on their behalf and how they will maintain oversight.

Planning the Transition Through a Structured Gap Assessment

A gap assessment provides a practical starting point for determining clinical trial readiness. It should examine the organisation's existing systems against the requirements and activities anticipated for the next development stage.

The assessment may cover:

  • Current quality system structure and governance.

  • Regulatory and quality responsibilities.

  • Document and record management.

  • Training and competency.

  • Data integrity arrangements.

  • Manufacturing and testing controls.

  • Supplier qualification and oversight.

  • Deviation, CAPA and change management.

  • Clinical trial sponsor responsibilities.

  • Electronic systems and information management.

  • Facilities, equipment and technical capabilities.

Findings should be classified according to their significance and the timing at which controls are required. Critical gaps affecting participant safety, product quality or regulatory compliance need appropriate attention before the relevant activity begins.

An implementation plan should assign responsibilities, target dates and resources. Progress should be reviewed regularly, with changes managed through appropriate governance.

This approach gives management visibility of readiness and helps prevent important activities from being delayed by avoidable quality or documentation problems.

Avoiding the Risks of Overbuilding

A common challenge for companies entering clinical development is deciding how much quality infrastructure to implement.

Too little structure can create compliance gaps, inconsistent practices and unreliable records. Too much complexity can make the system difficult to maintain, particularly when responsibilities are concentrated within a small team.

The answer is not to implement every possible procedure or purchase an extensive software platform before the organisation understands its needs.

Instead, quality infrastructure should be designed around actual activities and foreseeable development requirements. Procedures should be practical, responsibilities should be clear and controls should be proportionate to risk and regulatory expectations.

The organisation should also consider the next likely development milestone. A system designed only for current research activities may require substantial redesign when clinical manufacturing begins. Conversely, implementing commercial-scale systems prematurely can consume resources without providing corresponding value.

A planned, incremental approach allows the organisation to establish essential controls now and strengthen them as its programme develops.

Building Internal Capability for Clinical Trial Readiness

Quality systems are only effective when people understand and apply them. Personnel need appropriate knowledge of the procedures, regulatory expectations and responsibilities relevant to their work.

This is particularly important in organisations transitioning from research-led operations, where staff may have strong scientific expertise but limited experience with regulated development environments.

Training should address the practical application of quality principles, including document control, data integrity, deviation reporting, change management, risk assessment and relevant GxP responsibilities.

Management should also ensure that sufficient resources and authority are available to maintain quality oversight. Quality responsibilities cannot be effective if personnel lack the time, competence or organisational support to perform them.

Developing internal capability reduces dependence on external assistance for routine quality activities and supports more consistent decision-making as the organisation grows.

How QSN Can Support Your Next Development Stage

Preparing for a first clinical trial involves a series of connected decisions about quality systems, documentation, regulatory responsibilities and operational readiness.

Quality Systems Now supports therapeutic goods manufacturers, testing laboratories and biotechnology companies in developing practical GxP and regulatory compliance capabilities. Whether the priority is establishing a phase-appropriate PQS, designing the architecture for a controlled document management system or identifying the quality requirements associated with clinical trial preparation, the objective is to build a system that meets the organisation's needs without unnecessary complexity.

Support should be aligned with the company's current stage, planned activities and applicable regulatory obligations. This allows essential foundations to be established while keeping future development in view.

Conclusion

Scaling from R&D into a first clinical trial requires a deliberate transition from exploratory working practices to controlled, documented and appropriately governed activities.

The organisation must understand its regulatory responsibilities, establish a suitable quality system, manage documents and records effectively, protect data integrity and ensure appropriate oversight of manufacturing, testing and clinical service providers.

These foundations do not need to be unnecessarily complicated. They do need to be scientifically justified, proportionate to risk and suitable for the activities being performed.

By identifying gaps early, prioritising essential controls and developing internal capability, biotechnology and therapeutic goods companies can approach clinical development with greater clarity and confidence.

Whether you are preparing your first clinical trial or strengthening the systems needed to support the next stage of development, the right quality infrastructure can help you move forward without overbuilding for where you are today.

Back to Blog